邮件订阅 RSS 中文 | English
高级检索

来那度胺联合利妥昔单抗治疗1~3a级滤泡性淋巴瘤的疗效和安全性

Efficacy and safety of lenalidomide combined with rituximab in the treatment of grade 1-3a follicular lymphoma patients

    摘要
  • 摘要:
    目的 探讨来那度胺联合利妥昔单抗（R2）治疗1~3a级滤泡性淋巴瘤（follicular lymphoma，FL）的疗效和安全性。
    方法 选择2019年5月30日至2019年12月31日复旦大学附属中山医院血液科收治的12例采用R2治疗的1~3a级初发和复发FL患者。每28 d为1个周期，每周期的第1~7天和第15~22天口服来那度胺25 mg，共12周期；第1周期的第1、8、15、22天和第2~5周期的第1天静脉滴注R2注射液375 mg/m2，共5周期。每2~3个治疗周期进行疗效评价，主要评价指标为总体反应率（overall response rate，ORR）和无进展生存期（progression-free survival，PFS）。每周期前后进行安全性评价。
    结果 12例接受R2治疗的患者中，10例可疗效评价，ORR为88.9%，1年无进展生存率为87.5%，中位PFS未达到。3~4级中性粒细胞计数减少发生率为16.7%（2/12），3~4级肺部感染发生率为16.7%（2/12），未观察到3~4级的肝肾功能异常、皮疹、消化不良、周围神经病变。
    结论 来那度胺联合R2治疗1~3a级初发、复发FL患者可取得良好疗效和安全性。

     

    Abstract:
    Objective To explore the efficacy and safety of lenalidomide combined with rituximab in the treatment of grade 1-3a follicular lymphoma (FL) patients.
    Methods Twelve FL patients received lenalidomide combined with rituximab (R2) in Department of Hematology of Zhongshan Hospital, Fudan University between May 30, 2019 and Dec 31, 2019 were selected. Treatment with R2 consisted of lenalidomide 25 mg: d 1-7, d 15-22 on cycle 1-12, orally, and R2 375 mg/m2: d 1, 8, 15, 22 on cycle 1 and d 1 on cycle 2-5, intravenously. Every 28 days was one cycle. Efficacy was assessed every 2 to 3 cycles during the treatment. Efficacy was analyzed by overall response rate (ORR) and progression-free survival (PFS). Safety was assessed before and after each cycle.
    Results Among 12 patients received R2 regimen, the efficacy in 10 patients was evaluable, the ORR was 88.9%. One-year rate of PFS was 87.5% and median PFS was not reached. Grade 3-4 neutropenia and grade 3-4 pulmonary infection rates were both 16.7% (2/12). Grade 3-4 liver or renal function abnormality, rash, digestive symptoms, and peripheral nervous disease were not observed.
    Conclusions Lenalidomide combined with R2 is generally effective and safe in both untreated and relapsed grade 1-3a FL patients.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回